Linked Life Data

15701846

Source:http://linkedlifedata.com/resource/pubmed/id/15701846

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2 Pt 1
pubmed:dateCreated
2005-2-9
pubmed:abstractText
An association between epidermal growth factor receptor (EGFR) signaling pathway and response of cancer cells to ionizing radiation has been reported. Recently, a polymorphic variant in the EGFR gene that leads to an arginine-to-lysine substitution in the extracellular domain at codon 497 within subdomain IV of EGFR has been identified. The variant EGFR (HER-1 497K) may lead to attenuation in ligand binding, growth stimulation, tyrosine kinase activation, and induction of proto-oncogenes myc, fos, and jun. A (CA)(n) repeat polymorphism in intron 1 of the EGFR gene that alters EGFR expression in vitro and in vivo has also been described. In the current pilot study, we assessed both polymorphisms in 59 patients with locally advanced rectal cancer treated with adjuvant or neoadjuvant chemoradiation therapy using PCR-RFLP and a 5'-end [gamma-(33)P]ATP-labeled PCR protocol. We tested whether either polymorphism alone or in combination can be associated with local recurrence in the setting of chemoradiation treatment. We found that patients with HER-1 497 Arg/Arg genotype or lower number of CA repeats (both alleles <20) tended to have a higher risk of local recurrence (P = 0.24 and 0.31, respectively). Combined analysis showed the highest risk for local recurrence was seen in patients who possessed both a HER-1 497 Arg allele and <20 CA repeats (P = 0.05, log-rank test). Our data suggest that the HER-1 R497K and EGFR intron 1 (CA)(n) repeat polymorphisms may be potential indicators of radiosensitivity in patients with rectal cancer treated with chemoradiation.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
1078-0432
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
11
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
600-5
pubmed:dateRevised
2009-11-19
pubmed:meshHeading
pubmed-meshheading:15701846-Adult, pubmed-meshheading:15701846-Aged, pubmed-meshheading:15701846-Antineoplastic Agents, pubmed-meshheading:15701846-Caenorhabditis elegans Proteins, pubmed-meshheading:15701846-Chemotherapy, Adjuvant, pubmed-meshheading:15701846-DNA, Neoplasm, pubmed-meshheading:15701846-Female, pubmed-meshheading:15701846-Fluorouracil, pubmed-meshheading:15701846-Humans, pubmed-meshheading:15701846-Male, pubmed-meshheading:15701846-Middle Aged, pubmed-meshheading:15701846-Neoadjuvant Therapy, pubmed-meshheading:15701846-Neoplasm Recurrence, Local, pubmed-meshheading:15701846-Pilot Projects, pubmed-meshheading:15701846-Polymerase Chain Reaction, pubmed-meshheading:15701846-Polymorphism, Genetic, pubmed-meshheading:15701846-Polymorphism, Restriction Fragment Length, pubmed-meshheading:15701846-Receptor, Epidermal Growth Factor, pubmed-meshheading:15701846-Rectal Neoplasms, pubmed-meshheading:15701846-Repetitive Sequences, Nucleic Acid
pubmed:year
2005
pubmed:articleTitle
Epidermal growth factor receptor gene polymorphisms predict pelvic recurrence in patients with rectal cancer treated with chemoradiation.
pubmed:affiliation
Division of Medical Oncology and Department of Preventive Medicine, University of Southern California/Norris Comprehensive Cancer Center, Keck School of Medicine, Los Angeles, CA, USA.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S.